Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight rating and announces Price Target of $110.
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight rating and announces Price Target of $365.